دورية أكاديمية
أعرض في EDS

Correlation of serum homocysteine and cystatin C levels with prognosis in heart failure with preserved ejection fraction patients.

التفاصيل البيبلوغرافية
العنوان: Correlation of serum homocysteine and cystatin C levels with prognosis in heart failure with preserved ejection fraction patients.
المؤلفون: Chen ZH; Department of Cardiovascular Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China. 306724410@qq.com.; Department of Emergency Medicine, The Third People's Hospital of Hefei, Hefei, 230041, People's Republic of China. 306724410@qq.com., Zhu XT; Department of Cardiovascular Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China., Hu ZP; Department of Cardiovascular Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China., Ni JX; Department of Emergency Medicine, The Third People's Hospital of Hefei, Hefei, 230041, People's Republic of China., Chen HL; Department of Cardiovascular Medicine, The Third People's Hospital of Hefei, Hefei, 230041, People's Republic of China.
المصدر: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2024 Sep 27; Vol. 24 (1), pp. 510. Date of Electronic Publication: 2024 Sep 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968539 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2261 (Electronic) Linking ISSN: 14712261 NLM ISO Abbreviation: BMC Cardiovasc Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Homocysteine*/blood , Cystatin C*/blood , Stroke Volume* , Heart Failure*/blood , Heart Failure*/physiopathology , Heart Failure*/diagnosis , Heart Failure*/mortality , Biomarkers*/blood , Ventricular Function, Left* , Predictive Value of Tests*, Humans ; Male ; Female ; Aged ; Prognosis ; Middle Aged ; Risk Assessment ; Retrospective Studies ; Ventricular Remodeling ; Risk Factors
مستخلص: Objective: This study investigated the relationship of serum homocysteine (Hcy) and cystatin C (Cys C) levels with the prognosis of patients with heart failure with preserved ejection fraction (HFpEF).
Methods: A total of 178 patients with HFpEF who were admitted to our hospital between December 2019 and November 2020 were included. Patients were grouped based on their serum Hcy and Cys C levels: high Hcy level, normal Hcy level, high Cys C level, and normal Cys C level. Cardiac function, ventricular remodeling indices, and prognosis were compared among patients in these groups. Additionally, the predictive value of serum Hcy and Cys C levels for adverse cardiovascular events in HFpEF patients was analyzed.
Results: Patients' mean age in the high Hcy level, normal Hcy level, high Cys C level, and normal Cys C level groups was 69.21 ± 4.17,67.74 ± 4.28,69.95 ± 4.98, and 67.06 ± 4.13 years old, respectively. The high Hcy level group exhibited a lower proportion of class II cardiac function according to the New York Heart Association (NYHA) classification and a higher proportion of class IV cardiac function than the normal Hcy level group, with statistically significant differences. Similarly, the high Cys C level group had a lower proportion of class II cardiac function and a higher proportion of class IV cardiac function compared with the normal Cys C level group, with statistically significant differences. Left ventricular end-diastolic internal diameter (LVEDD), left ventricular end-systolic internal diameter (LVESD), and left ventricular mass index (LVMI) were significantly higher in both the high Hcy level and high Cys C level groups compared with the normal group, with statistically significant differences. The rates of all-cause mortality and class I endpoint events were significantly higher in the high Hcy level and high Cys C level groups than in the normal group. Multifactorial logistic regression analysis demonstrated that adverse cardiovascular events were significantly associated with cardiac function class, LVEDD, LVESD, LVMI, Hcy, and Cys C in patients with HFpEF. The area under the curve (AUC) values for Hcy and Cys C, determined using receiver operating characteristic (ROC) curve analysis, were 0.778 (optimal critical value, 25.38) and 0.681 (optimal critical value, 1.56), respectively, for predicting adverse cardiovascular events. Both Hcy and Cys C serum levels were positively correlated with LVEDD, LVESD, LVMI, and NYHA classification.
Conclusion: Serum levels of Hcy and Cys C were closely associated with cardiac function, ventricular remodeling indices, and prognosis in patients with HFpEF. These levels may serve as valuable indices for assessing HFpEF patients' health status and prognosis, providing important insights into their potential role as biomarkers for HFpEF management and prognosis.
(© 2024. The Author(s).)
References: Ther Adv Cardiovasc Dis. 2017 Nov;11(11):283-295. (PMID: 28830298)
RSC Adv. 2018 Mar 5;8(17):9519-9523. (PMID: 35541868)
Clin Res Cardiol. 2010 May;99(5):323-8. (PMID: 20130888)
J Clin Invest. 2000 Jul;106(1):55-62. (PMID: 10880048)
Circ Res. 1998 Mar 9;82(4):482-95. (PMID: 9506709)
J Card Fail. 2011 Jan;17(1):31-8. (PMID: 21187262)
Eur Heart J. 2008 Oct;29(19):2388-442. (PMID: 18799522)
Ann Intern Med. 2005 Apr 5;142(7):497-505. (PMID: 15809461)
Arch Pharm Res. 2018 Apr;41(4):372-383. (PMID: 29552692)
Circ Res. 2019 May 24;124(11):1598-1617. (PMID: 31120821)
Z Gerontol Geriatr. 2018 Jan;51(1):92-97. (PMID: 27206415)
Nat Rev Cardiol. 2020 Sep;17(9):559-573. (PMID: 32231333)
N Engl J Med. 2000 Oct 19;343(16):1139-47. (PMID: 11036119)
RSC Adv. 2019 Mar 12;9(14):7955-7960. (PMID: 35521186)
Heart. 2018 Mar;104(5):377-384. (PMID: 29305560)
Blood Purif. 2014;37(4):304-10. (PMID: 25170751)
Cardiology. 2010;117(1):21-7. (PMID: 20881390)
J Anaesthesiol Clin Pharmacol. 2018 Apr-Jun;34(2):161-165. (PMID: 30104821)
Circ Heart Fail. 2009 Mar;2(2):86-9. (PMID: 19808322)
Eur Heart J. 2013 May;34(19):1424-31. (PMID: 23470495)
Heart Lung Circ. 2020 Jan;29(1):62-68. (PMID: 31311687)
Clin Lab. 2015;61(9):1137-45. (PMID: 26554232)
Eur Heart J. 2019 Oct 21;40(40):3297-3317. (PMID: 31504452)
فهرسة مساهمة: Keywords: Cardiac function; Cystatin C; Ejection fraction preserved heart failure; Homocysteine; Prognosis; Ventricular remodeling
المشرفين على المادة: 0LVT1QZ0BA (Homocysteine)
0 (Cystatin C)
0 (Biomarkers)
0 (CST3 protein, human)
تواريخ الأحداث: Date Created: 20240926 Date Completed: 20240927 Latest Revision: 20240929
رمز التحديث: 20240929
مُعرف محوري في PubMed: PMC11428330
DOI: 10.1186/s12872-024-04058-9
PMID: 39327565
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2261
DOI:10.1186/s12872-024-04058-9